Boretti Alberto
Independent Scientist, Johnsonville, Wellington, New Zealand.
Eur J Pharmacol. 2024 Jul 5;974:176618. doi: 10.1016/j.ejphar.2024.176618. Epub 2024 Apr 26.
Cancer poses a formidable challenge in the field of medical science, prompting the exploration of innovative and efficient treatment strategies. One revolutionary breakthrough in cancer therapy is Chimeric Antigen Receptor (CAR) T-cell therapy, an avant-garde method involving the customization of a patient's immune cells to combat cancer. Particularly successful in addressing blood cancers, CAR T-cell therapy introduces an unprecedented level of effectiveness, offering the prospect of sustained disease management. As ongoing research advances to overcome current challenges, CAR T-cell therapy stands poised to become an essential tool in the fight against cancer. Ongoing enhancements aim to improve its effectiveness and reduce time and cost, with the integration of Artificial Intelligence (AI) and Internet of Things (IoT) technologies. The synergy of AI and IoT could enable more precise tailoring of CAR T-cell therapy to individual patients, streamlining the therapeutic process. This holds the potential to elevate treatment efficacy, mitigate adverse effects, and expedite the overall progress of CAR T-cell therapies.
癌症在医学领域构成了一项艰巨挑战,促使人们探索创新且高效的治疗策略。癌症治疗领域的一项革命性突破是嵌合抗原受体(CAR)T细胞疗法,这是一种前沿方法,涉及对患者免疫细胞进行定制以对抗癌症。CAR T细胞疗法在治疗血癌方面尤为成功,带来了前所未有的疗效,为持续的疾病管理提供了前景。随着正在进行的研究不断推进以克服当前挑战,CAR T细胞疗法有望成为抗击癌症的重要工具。正在进行的改进旨在提高其疗效并减少时间和成本,同时整合人工智能(AI)和物联网(IoT)技术。AI和IoT的协同作用能够使CAR T细胞疗法更精确地针对个体患者进行定制,简化治疗过程。这有可能提高治疗效果、减轻不良反应并加速CAR T细胞疗法的整体进展。